A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Persistent Obesity or Overweight Treated with a Weekly Incretin with and without Type 2 Diabetes (ENLIGHTEN-6)

Brief description of study

The purpose of this study is to learn more about eloralintide, a possible new treatment for obesity and for those that are overweight as an add on treatment to a medication called an incretin in people with or without type 2 diabetes. Incretins are medicines that help lower blood sugar and reduce appetite.

Clinical Study Identifier: s25-01586

ClinicalTrials.gov Identifier: NCT07392190

Principal Investigator: Holly F Lofton.

Other Investigator: Kelly Minus.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies